Tuesday, September 3, 2013

Three Abstracts from Advaxis, Inc. (ADXS) Accepted for Presentation at Society for Immunotherapy of Cancer Annual Meeting

Advaxis, a leader in developing the next generation of immunotherapies for cancer and infectious diseases, was pleased to announce today that three abstracts describing research with Advaxis Lm-LLO immunotherapies have been selected for poster presentation at the Society for Immunotherapy of Cancer (SITC) 28th Annual Meeting. This year’s meeting will take place November 8-10, 2013, at the Gaylord National Hotel & Convention Center in National Harbor, MD.

The abstract titled “Listeria monocytogenes (Lm)-LLO immunotherapies reduce the immunosuppressive activity of myeloid-derived suppressor cells and regulatory T cells in the tumor microenvironment” has been selected for oral presentation during the session, “Tumor Microenvironment and Innate Cells Recognition” on November 8, 2013 from 9:40 AM to 12:00 PM. Anu Wallecha, Ph.D., Director of Research and Development at Advaxis, will report on the localized effects of Lm-LLO immunotherapies on the tumor microenvironment in preclinical studies using transplantable mouse models.

The abstract titled “ADXS11-001 immunotherapy targeting HPV-E7: Updated survival and safety data from a Phase 2 study in Indian women with recurrent/refractory cervical cancer” has been selected for poster presentation during the Vaccine session. Robert Petit, Ph.D., Chief Scientific Officer of Advaxis, will present final 18-month survival and updated safety data from the ongoing trial.

The abstract titled “Biomarker identification in serum samples from patients with recurrent cervical cancer treated with ADXS11-001 immunotherapy” has been selected for poster presentation during the session “Biomarkers and Immunoscoring”. Poonam Molli, Ph.D., Senior Scientist at Advaxis, will report on the correlation of changes in cytokine and chemokine levels pre- and post-dosing with ADXS11-001 from the Phase 2 study in Indian women with recurrent/refractory cervical cancer.

“The three presentations of Advaxis data at SITC reflect our growing understanding of the unique attributes of the Advaxis platform technology for immunotherapies. Dr. Wallecha’s presentation will highlight the ability of Lm-LLO immunotherapy to counteract immune suppressor cells that enable persistence of the tumor. We will report final 18-month survival and final tumor response data from our 110 patient Phase 2 study in India in women with recurrent cervical cancer. Dr. Molli’s presentation will illustrate the remarkable immune stimulation that occurs in patients after treatment with ADXS11-001. Together, these data paint a picture of an immunotherapy that has a strong positive impact on the immune system while at the same time counteracting immune suppression in the tumor microenvironment that can lead to apparent prolonged survival and objective tumor responses from a single immunotherapeutic agent,” commented Dr. Petit.

For additional information, please visit: www.ADXS.MissionIR.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website
http://www.missionir.com/disclaimer.html

Chanticleer Holdings, Inc. (HOTR) Secures Prime Restaurant Location in Pretoria, South Africa

Chanticleer Holdings, a minority holder in the privately held parent company of the Hooters brand Hooters Of America, and a franchisee of international Hooters restaurants, today announced that it has secured a prime lease in Pretoria, South Africa. This location, which is expected to open before the end of this year, will bring the company’s total number of international Hooters restaurants to eight in three countries.

The new Hooters in Pretoria will be built in The Willows Shopping Centre, in the eastern part of Pretoria. Gordon Jestin, Chanticleer’s Chief Operating Officer for Hooters, South Africa, stated, “This is a busy, high-traffic area where its residents tend to live and shop within a 5 mile radius of The Willows Shopping Centre, making this a perfect location for a Hooters restaurant.” Jestin continued, “This strip centre affords our customers convenience and ample parking in a busy traffic pattern with more than an estimated 4,000 cars passing our site per day. We have executed a 5 year lease with a 5 year option to renew for 7,700 square feet, including a brilliant outside balcony space, with very favorable terms, including landlord-provided upfits in the buildout. We are right in the middle of a number of fast food restaurants and retail stores with the perfect demographics for our Hooters.”

Mike Pruitt, Chairman and Chief Executive Officer, commented, “South Africa, for many reasons, has been an outstanding market for our Hooters brand. Our locations continue to grow, partly due to the sports-loving nature of the South African people who can now watch sporting activities on many of the largest High Definition TVs, unique in the country, while enjoying our new menu items. That, combined with the famous Hooters girls and vibrant atmosphere, makes Hooters a destination restaurant.” Pruitt said further, “We now have Hooters restaurants in Europe, South Africa and Australia, and soon to be in the United Kingdom and Brazil, demonstrating that our American brand is becoming an integral part of leisure dining in these international markets. The recently announced Letter of Intent to acquire American Roadside Burgers, a 5 restaurant chain operating primarily in the Carolinas, gives us a growth opportunity here at home and abroad as well.”

For more information, please visit www.chanticleerholdings.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website
http://www.missionir.com/disclaimer.html

New York State Department of Health Grants Lab Permit to Genetic Technologies Ltd. (GENE)

Genetic Technologies announced this week that it has received its Clinical Laboratory Permit from the New York State Department of Health.

In late July, the DoH Clinical Laboratory Evaluation Program inspected the company’s Melbourne laboratories; following the two-day audit, the company received a Laboratory Evaluation Report with “no significant deficiencies,” allowing for the immediate issue of the permit.

This permit allows Genetic Technologies to meet requests received from New York physicians to provide the BREVAGen™ test to their patients and completes the out-of-state licensures that allows the company to provide testing services to all 50 U.S. states.

Having New York State as part of its territory will augment the current market adoption, which the company notes is delivering significant increases in the number of test samples provided to the laboratory during the current quarter to date.

“This is a wonderful endorsement of the quality of our laboratory systems and the validation package provided by our highly qualified staff,” said Alison Mew, Genetic Technologies’ CEO. “Importantly, it also allows women across the United States access to BREVAGen™ to deliver comprehensive breast health care.”

For more information, visit www.gtglabs.com

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website
http://www.missionir.com/disclaimer.html

Galena Biopharma (GALE) Initiates RELIEF Patient Registry for Abstral®, Launches Sales Campaign

Galena Biopharma, a Portland -based biopharmaceutical company focused on developing innovative, targeted oncology treatments to advance cancer care, this morning reports the initiation of its registry study entitled RELIEF: Rapid Evaluation of Lifestyle, Independence, and Elimination of breakthrough cancer pain with Freedom from oral discomfort through the use of Abstral® (fentanyl) Sublingual Tablets.

The Institutional Review Board (IRB)-approved cancer patient registry study is a post-marketing multicenter trial to assess Abstral for breakthrough cancer pain (BTcP) in opioid-tolerant cancer patients. Abstral is currently available to patients and health care professionals at pharmacies nationwide.

GALE has begun recruitment and enrollment of approximately 2,500 patients. RELIEF is expected to be completed by enrolled patients over a 30-day period while using Abstral for treatment of their breakthrough cancer pain.

“With collaboration and support from the physician community, we are excited to initiate our RELIEF trial and debut Abstral this week, which we believe is the best product in this class of drugs for patients suffering from breakthrough cancer pain,” Mark J. Ahn, GALE’s president and CEO stated in the press release. “Abstral’s product features, including its ease of use, and lack of product disposal issues, make it an important treatment option for these patients,” he said. “The RELIEF registry is a critical initiative that will help assess the attributes of the drug and provide a sizeable data set to support physicians who prescribe Abstral.”

GALE also said it has kicked-off Abstral’s sales and marketing campaign at PAINWeek, one of the nation’s largest pain conferences, held in Las Vegas, NV, September 4-7, 2013. GALE has fully staffed its commercial team in preparation for a fourth-quarter launch, backed by senior level executives and a highly experienced sales force.

“The initiation of our registry program ahead of our official launch is an important first step in our overall commercial plan as the second half of the year will be transformational for Galena, as we generate sales and become a revenue producing organization,” concluded Ahn.

For more information, visit www.galenabiopharma.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website
http://www.missionir.com/disclaimer.html

How Much Effect Does the Twitterverse Have on Wall Street?

Social media has penetrated nearly every avenue of the business world. From the release of company news and spreading brand awareness to bridging employee/employer communication and employee recruitment, the applications for social media in the public marketplace are endless. Take notice, investors, because social media long ago penetrated Wall Street as well.

In 2010, Johan Bollen, a computer scientist at Indiana Bloomington, investigated whether the mass emotions and moods expressed by the public on Twitter feeds were connected to the performance of the Dow Jones Industrial Average. Bollen’s research led to the discovery of a pattern in which the Dow rose over a few days of “calm” tweets and sagged after a few days of tweets with “anxious” sentiment. From his algorithms, Bollen predicted the direction of the Dow’s closing price with nearly 88 percent accuracy.

Bollen’s research is three years old. In the grand scheme of things, three years isn’t long, but insurmountable changes within social media and technology have obviously taken place since then. However, in this case, the passage of time by no means voids the findings, but rather, accentuates them.

It is estimated that the Twitterverse has grown to more than 4 million tweets each day, countless numbers of them coming from innovative businesses leveraging the latest social networking trends for their benefit. People tend to think in masses, lining up with like-minded individuals to stand behind or against a cause and/or company in any industry offering any service. It’s important for companies to be transparent, truthful, and consistent with their followers, because with the power of a single tweet or Facebook post, a small bit of bad PR can go a long way in a matter of seconds. Anyone paying the slightest bit of attention to the use of social media in the market has seen how 140 characters can affect a stock’s movement.

Public companies have an obligation to themselves to keep a handle on their social media use (Twitter is only one of many). The masses are talking and their message has an effect on how a company is perceived by an audience it often doesn’t even know it has. It is for this reason that companies like SocialMediaRelations.us exist. A professional social media campaign manager not only maximizes the reach and effectiveness of a company’s outreach, but can also advise and execute damage control in the event of bad publicity on the Web.

Whether Bollen’s algorithm carries a legitimate, significant weight can only be proven or squelched by additional research, though it’s an intriguing find, nonetheless. On a smaller scale than the actual Dow, Wall Street and its players are unarguably affected by social media, and it’s up to each company to use social media to its advantage.

For more information on social media relations, visit www.socialmediarelations.us

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website
http://www.missionir.com/disclaimer.html

Cardium Therapeutics Inc. (CXM) Using the Heart’s Natural Healing Process to Revolutionize Cardiovascular Therapy

Cardiovascular disease is responsible for 17 million deaths around the globe, making it the No. 1 cause of death worldwide, according to the American Heart Association and the World Health Organization. The disease is often onset by poor lifestyle choices, resulting in healthcare services, medications, and lost productivity that costs the United States more than $108 billion each year.

If individuals aren’t taking responsibility for their own health, the burden falls to forward-thinking companies willing to put in the time, effort, and research to address the disease and develop advanced therapies for treatment.

Cardium Therapeutics is a health sciences company focused on combining the mysterious complexity of biology with the power of regenerative medicine to develop new ways to treat cardiovascular disease and its morbid weight on the human race. The company’s strategy oversteps conventional approaches such as drug therapy, which only provides temporary relief, and invasive treatment options such as bypass surgery, angioplasty, and stents.

CXM’s medical portfolio includes Generx, a non-surgical angiogenic treatment option that actually enhances cardiac blood flow. Generx aligns with the heart’s natural healing process, using DNA to encourage microvascular blood vessel growth (angiogenesis) within the heart.

CXM believes that its angiogenic therapeutic approach is remarkably different from other potential angiogenic therapies, and that its approach holds several advantages over competitors. One such advantage is its intracoronary deliver technique, which utilizes a standard diagnostic catheter, creating the potential for a wider distribution of therapeutic material in the heart, as compared to direct needle injections into portions of the heart muscle.

The lead candidate has progressed through four randomized, placebo-controlled clinical studies at more than 100 medical centers in the United States and Western Europe that have enrolled more than 650 patients. CXM reports that within eight weeks of administering its Generx therapy, patients have experienced improved cardiac perfusion and angiogenesis.

For more information, visit www.CardiumThx.com

Please see disclaimer on the MissionIR website
http://www.missionir.com/disclaimer.html

Mabwe Minerals, Inc. (MBMI) Gears Up for Production

Mabwe Minerals, a natural resources and hard asset company based in the United States, is focused on the mining, logistics, and commercial sales of industrial minerals and metals. The company’s first mineral production focus is on barite.

Mabwe Minerals conducts its operations through its Zimbabwe parent/holding affiliate, Mabwe Corporation Limited, which includes wholly owned subsidiary Mabwe Minerals Zimbabwe Limited and the minority owned WGB Kinsey & Company. Ninety-million shares, or around 66%, of Mabwe Minerals’ outstanding shares of common stock are owned by Raptor Resources Holdings.

Mabwe Minerals owns 100% of the Dodge Mine in Shamva, Zimbabwe, which hosts barite, limestone, and talc, with widespread gossan deposits indicating the potential presence of copper, zinc, nickel, and gold. Located on the southern edge of the Shamva Greenstone Belt, Dodge Mine is composed of Precambrian metamorphosed sediments of the Grahamsdale Formation. Dodge Mine is a hydrothermal mountain range that implies high quality deposits of minerals and metals.

The company has secured a long-term master supplier agreement (MSA) with Baker Hughes, Inc. that represents 3,000,000 metric tons of barite. Calculated at an average 2012 price of $150/ton, this agreement represents $450 million.

Through an equity investment, Mabwe Minerals currently owns 25% of WGB Kinsey & Company, one of the most experienced mining and construction companies in Zimbabwe. WGB Kinsey & Company will be responsible for all operations at Dodge Mine. With both open pit and open cast mining experience ranging from chrome to platinum to gold, WGB Kinsey & Company possesses all the necessary equipment and management expertise to manage Dodge Mine.

In August 2013, Mabwe Minerals entered into strategic alliances with both Steinbock Minerals Ltd. and Yasheya Ltd. The Switzerland-based Steinbock Minerals will serve as the company’s distributor and sales arm, while globally recognized leader Yasheya will serve as the company’s shipping and delivery arm. Through these alliances, Mabwe Minerals’ distribution, sales, shipment and delivery network has been successfully established.

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.

Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net